Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
2015年9月18日 更新者:Allergan
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
研究概览
研究类型
介入性
注册 (实际的)
52
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
California
-
San Francisco、California、美国
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 65年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- History of chronic migraine for at least 6 months prior to the screening visit
- Fifteen or more headache days during the 4-week screening period (≥4 headache episodes lasting ≥4 hours and ≥50 % of headache days are migraine)
Exclusion Criteria:
- Conditions causing chronic facial pain such as Temporomandibular Disorder (TMD) and fibromyalgia
- Use of headache prophylaxis medication within 4 weeks of the screening visit
- Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
- Previous use of any botulinum toxin of any serotype for any reason
- Skin infections or acne that would interfere with the injection sites
- Acupuncture, transcutaneous electrical nerve stimulation (TENS), cranial traction, dental splints for headache, nociceptive trigeminal inhibition, occipital nerve block treatments, or injection of anesthetics/steroids within 4 weeks of screening.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:OnabotulinumtoxinA
OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
|
OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
其他名称:
|
|
安慰剂比较:Placebo (Normal saline)
Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
|
Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire Total Score
大体时间:Baseline, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The total score ranged from 0 (lower impact chronic migraine) to 100 (highest impact chronic migraine).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening.
|
Baseline, Week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in the Symptom Severity Score (SSS) Subdomain of the Assessment of Chronic Migraine Symptoms (ACM-S) Questionnaire
大体时间:Baseline, Week 24
|
The ACM-S is 12 question migraine symptom scale over the past 24 hours.
The SSS subdomain score ranges from 0 (no symptoms) to 100 (more severe symptoms).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the ACM-S SSS.
|
Baseline, Week 24
|
|
Change From Baseline in the Symptom Experience Score (SES) Subdomain of the ACM-S Questionnaire
大体时间:Baseline, Week 24
|
The ACM-S is 12 question migraine symptom scale over the past 24 hours.
The SES subdomain score ranges from 0 (no symptoms) to 12 (all symptoms experienced).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the ACM-S SES.
|
Baseline, Week 24
|
|
Change From Baseline in the Activities of Daily Living Impact (ADL-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The ADL-I is a subdomain on the ACM-I.
The ADL-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the ADL-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Emotions Impact (EMO-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The EMO-I is a subdomain on the ACM-I.
The EMO-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the EMO-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Work/School Impact (WS-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The WS-I is a subdomain on the ACM-I.
The WS-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the WS-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Social Impact (SOC-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The SOC-I is a subdomain on the ACM-I.
The SOC-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the SOC-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Leisure Activities Impact (LEA-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The LEA-I is a subdomain on the ACM-I.
The LEA-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the LEA-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Household Activities Impact (HOS-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The HOS-I is a subdomain on the ACM-I.
The HOS-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the HOS-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Energy Impact (ENE-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The ENE-I is a subdomain on the ACM-I.
The ENE-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the ENE-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Cognitive Impact (COG-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The COG-I is a subdomain on the ACM-I.
The COG-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the COG-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the General Impact (GEN-I) Domain of the ACM-I Questionnaire
大体时间:Baseline, Week 12, Week 22, Week 24
|
The ACM-I is a 24 question scale used to measure the impact of chronic migraine on daily activities and patient-treatment benefit over the past 7 days.
The GEN-I is a subdomain on the ACM-I.
The GEN-I score ranged from 0 (lowest impact) to 100 (highest impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the GEN-I.
|
Baseline, Week 12, Week 22, Week 24
|
|
Change From Baseline in the Headache Impact Test-6 (HIT-6) Questionnaire Total Score
大体时间:Baseline, Week 24
|
The HIT-6 is a 6 question 5-point scale used to measure the impact of headaches on daily life.
The total score ranged from 36 (no impact) to 78 (worst impact).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening.
|
Baseline, Week 24
|
|
Change From Baseline in the Role Function-Restrictive (RR) Domain of the Migraine Specific Questionnaire (MSQ)
大体时间:Baseline, Week 24
|
The MSQ is 14 question scale that measures health-related impairments attributed to migraines over the past 4 weeks.
The RR domain score ranges from 0 (no symptoms) to 100 (symptoms experienced all the time).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the RR.
|
Baseline, Week 24
|
|
Change From Baseline in the Role Function-Preventive (RP) Domain of the MSQ
大体时间:Baseline, Week 24
|
The MSQ is 14 question scale that measures health-related impairments attributed to migraines over the past 4 weeks.
The RP domain score ranges from 0 (no symptoms) to 100 (symptoms experienced all the time).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the RP.
|
Baseline, Week 24
|
|
Change From Baseline in the Emotional Function (EF) Domain of the MSQ
大体时间:Baseline, Week 24
|
The MSQ is 14 question scale that measures health-related impairments attributed to migraines over the past 4 weeks.
The EF domain score ranges from 0 (no symptoms) to 100 (symptoms experienced all the time).
A negative number change from baseline indicates an improvement, and a positive number change from baseline indicates a worsening in the EF.
|
Baseline, Week 24
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2013年4月1日
初级完成 (实际的)
2014年9月1日
研究完成 (实际的)
2014年9月1日
研究注册日期
首次提交
2013年4月12日
首先提交符合 QC 标准的
2013年4月12日
首次发布 (估计)
2013年4月16日
研究记录更新
最后更新发布 (估计)
2015年10月21日
上次提交的符合 QC 标准的更新
2015年9月18日
最后验证
2015年9月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.